Xeno Diagnostics

Xeno Diagnostics operates as a specialized CRO providing essential immunological assay services to biotech and pharmaceutical companies. The company leverages decades of collective experience to design and execute custom cell-based assays, including its signature Mixed Lymphocyte Reactions, to assess immune responses to therapeutics. Its services are crucial for product development and regulatory submissions, particularly for complex modalities like cell therapies, biologics, and implantable materials. Xeno positions itself as a strategic partner, supporting clients from early research through mid-phase clinical trials with a focus on immuno-oncology, regenerative medicine, and transplant immunology.

Integrated suite of custom cell-based immunoassays, specializing in Mixed Lymphocyte Reactions (MLR). Utilizes ELISA, Flow Cytometry, and Luminex multiplex technology for endpoint analysis of immune cell proliferation, activation, cytotoxicity, and cytokine secretion.

Xeno competes in the niche of specialized immunology CRO services against other boutique firms and the specialized divisions of large, global CROs. Its differentiation is its deep focus on MLR and cell-based immunoassays for novel therapies, a reputation built on decades of collective experience, and a client-centric partnership model.